Company Analysis

Exelixis, Inc. (EXEL)

Nasdaq: EXEL · Biological Products, (No Diagnostic Substances) · Alameda, CA · filing with the SEC since 2000
Grade7.5
◀ Past 8.6● Present 8.5▶ Future 5.1

Who runs Exelixis, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Morrissey Michael
President and CEO. First filing Dec 2006, latest May 19, 2026, 38 filings in all.
Officers reporting now
5
of 16 people with a filing in the last fifteen months
Directors reporting now
11
28 people on the record since 2006
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Aftab DanaEVP, Research and DevelopmentDec 2022May 28, 20264 · $7.7M
Haley Patrick J.EVP, CommercialDec 2016May 22, 20267 · $7.6M
Morrissey MichaelPresident and CEODec 2006May 19, 2026none
Senner Christopher J.EVP and CFOJul 2015May 19, 20263 · $4.6M
Hefti BrendaSVP and General CounselNov 2025May 19, 20262 · $1.2M
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameRoleFirst filingLatest filingSales, 12 months
Beckerle Mary CdirectorJan 2024Aug 12, 20264 · $1.9M
Eckhardt Sue GaildirectorJan 2024Jun 3, 20262 · $700,000
Wyszomierski Jack LdirectorMay 2006Jun 3, 20262 · $4.6M
Caligan Partners LPdirectorMay 2023May 29, 2026none
Freire Maria CdirectorApr 2018May 29, 20261 · $900,000
Heyman Tomas J.directorMay 2023May 29, 2026none
Johnson David EdwarddirectorMay 2023May 29, 2026none
Oliver BobdirectorMay 2023May 29, 20262 · $1.3M
Papadopoulos SteliosdirectorMay 2006May 29, 20261 · $4.4M
Poste GeorgedirectorMay 2006May 29, 20261 · $2.7M
Smith JuliedirectorSep 2016May 29, 20263 · $4.7M
Earlier names on the record12, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton EXEL · research, not advice